Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Work In Process (2016 - 2022)

Usana Health Sciences has reported Work In Process over the past 12 years, most recently at $8.0 million for Q3 2022.

  • Quarterly Work In Process fell 7.44% to $8.0 million in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $8.0 million through Jul 2022, down 7.44% year-over-year, with the annual reading at $9.6 million for FY2022, 3.72% down from the prior year.
  • Work In Process was $8.0 million for Q3 2022 at Usana Health Sciences, down from $9.7 million in the prior quarter.
  • Over five years, Work In Process peaked at $14.5 million in Q4 2018 and troughed at $8.0 million in Q3 2022.
  • The 5-year median for Work In Process is $10.0 million (2018), against an average of $10.7 million.
  • Year-over-year, Work In Process skyrocketed 71.2% in 2018 and then plummeted 39.12% in 2020.
  • A 5-year view of Work In Process shows it stood at $14.5 million in 2018, then dropped by 16.39% to $12.1 million in 2019, then fell by 29.85% to $8.5 million in 2020, then increased by 22.14% to $10.4 million in 2021, then decreased by 23.0% to $8.0 million in 2022.
  • Per Business Quant, the three most recent readings for USNA's Work In Process are $8.0 million (Q3 2022), $9.7 million (Q2 2022), and $9.6 million (Q1 2022).